A recently published study on therapy for antineutrophil cytoplasmic autoantibody-associated small vessel vasculitis has provided answers but not clarity towards defining how best to treat patients with vasculitis. How do we use recent advances in knowledge to optimally influence our patients' outcomes without causing harm in the process?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
Current Treatment Options in Rheumatology Open Access 13 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Nachman, P. H., Hogan, S. L., Jennette, J. C. & Falk, R. J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7, 33–39 (1996).
Guillevin, L. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis [see comments]. Arthritis Rheum. 40, 2187–2198 (1997).
de Groot, K., Adu, D. & Savage, C. O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. 16, 2018–2027 (2001).
de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).
Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2011-200477.
Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621–631 (2005).
Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908–2918 (2008).
Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
McGregor, J., Falk, R. The elusive optimal induction strategy for vasculitis. Nat Rev Nephrol 8, 195–196 (2012). https://doi.org/10.1038/nrneph.2012.16
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.16
This article is cited by
-
Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
Current Treatment Options in Rheumatology (2017)
